1. Sponsored

IRA Reality Check: Four Strategies for Adapting Hub and Copay Programs

Written by Posted on Less than 0 min read

Today’s guest post comes from Chris Dowd, Senior VP of Market Development at ConnectiveRx.

Chris reviews recent developments for the Inflation Reduction Act of 2022 (IRA). He then recommends four IRA-related adjustments that manufacturers should make to their patient support programs.

To learn more, register for ConnectiveRx’s free webinar on September 17: IRA Reality Check: Adapting Hub and Copay Programs to Ensure Patient Access and Affordability.

Read on for Chris’s insights.

Read more »

© 2006-2024 HMP Omnimedia, LLC d/b/a Drug Channels Institute, an HMP Global Company. All rights reserved. This Feed is for personal non-commercial use only.

       
View Original Article
Member since
Expert insights from Dr. Adam J. Fein on pharmaceutical economics and the drug distribution system. https://www.drugchannels.net/
Do you like Drug Channels's articles? Follow on social!

More from Drug Channels

  1. Corporate Finance

Rethinking Financial Services in Biopharma Patient Affordability Programs

Today’s guest post comes from Bob Raffo, Senior Vice President of Financial Services & Strategic Commercial Development at Cencora. Bob discusses the challenges faced by patient affordability programs managed by third-party vendors. He explains three ways that biopharma companies can benefit by working with a financial services provider specializing in patient affordability programs. Click here […]
2 min read
0
  1. Media & Marketing

Vertical Integration Lessons: The Economics and Strategies of Hospital-Owned Specialty Pharmacies

As many of you know, hospitals and health systems have emerged as significant participants in the specialty pharmacy industry. A new American Society of Hospital Pharmacists (ASHP) survey provides fresh insights into these specialty pharmacies. Below, I review key findings on the economics and operations of these specialty pharmacies. I then highlight how hospitals steer […]
2 min read
0
  1. Trends & External Forces

Drug Wholesalers and Brand-Name Drug Prices: Understanding CVS Health/McKesson and Why Pharmacies Lose Money on GLP-1s

Consider two apparently unrelated drug channel anomalies: In McKesson’s 2023 fiscal year, CVS bought $75 billion in pharmaceuticals from McKesson’s wholesale business—a jump of more than 35% compared with the previous year. Despite skyrocketing sales for anti-obesity GLP-1 drugs, many retail pharmacies are losing money on every prescription. The common factor behind these two disparate […]
2 min read
0
  1. Trends & External Forces

HCP Perspectives: Access Challenges in Treating Diabetes & Obesity

Today’s guest post is from Dr. Preeti Parikh, a practicing pediatrician and VP, Executive Medical Director at GoodRx. At the recent Publicis Health Media HealthFront event, Preeti hosted a dialogue on the main stage with Dr. Minisha Sood. They discussed new GoodRx research and had a candid discussion about their daily challenges in caring for […]
2 min read
0
  1. Media & Marketing

BIG NEWS! HMP Global Acquires Drug Channels Institute

Paula and I have some exciting news to share with you: Drug Channels Institute is joining the HMP Global family! HMP is a leading omnichannel healthcare education, events, and market insights company. It’s a great fit for DCI. Here’s the press release: HMP Global Expands Market Reach with Strategic Acquisition of Drug Channels Institute; Launches […]
2 min read
0
  1. Channel: Drug

Humira Biosimilar Price War Update: Should We Be Glad that CVS Health and Express Scripts Are Using Private Label Products to Pop the Gross-to-Net Bubble? (rerun)

This week, I’m rerunning some popular posts while I prepare for Friday’s Drug Channels Outlook 2025 live video webinar. Click here to see the original post. During Friday’s webinar, I’ll share some updated thoughts on biosimilars and PBM’s private label products. The Humira biosimilar market just took another step forward—but remains far from its ideal state. […]
2 min read
0
  1. Trends & External Forces

Medicare Part D in 2024: Smaller Pharmacies Abandon Preferred Pharmacy Networks

In a previous article, I highlighted the largest pharmacy chains that will participate in the 2024 Medicare Part D prescription drug plans (PDP). Today, I update DCI’s exclusive analysis of how smaller pharmacies will participate as preferred cost sharing pharmacies via the pharmacy services administrative organizations (PSAOs) that represent them in negotiations with plans. As […]
2 min read
0
  1. Data & Insights

GoodRx: Evolving & Expanding Integrated Platform Partnerships to Drive Access, Affordability & Outcomes

Today’s guest post comes from Rick Fry, VP of Strategic Development at GoodRx. Rick explains why patients and pharmaceutical manufacturers now pay a greater share of prescription costs. He outlines GoodRx’s services that address the twin challenges when the patient is the payer and the manufacturer faces intense gross-to-net pressures. To learn more, download the […]
2 min read
0
  1. Department: HBC

Today’s Rare Disease Launches Require the Right Specialty Pharmacy Partner

Today’s guest post comes from Richard Faris, Chief Strategy & Growth Officer at PANTHERx Rare Pharmacy. Richard outlines the key factors for commercialization success when a manufacturer launches treatments for rare and orphan diseases. He explains the key considerations for choosing a specialty pharmacy network design, selecting the right pharmacy partners, and establishing patient services […]
2 min read
0
  1. Data & Insights

Gross-to-Net Bubble Update: 2022 Pricing Realities at 10 Top Drugmakers (rerun)

This week, I’m rerunning some popular posts while I put the finishing touches on DCI’s new 2023-24 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors. Click here to see the original post from June 2023. Time for Drug Channels’ annual update on pricing at the largest pharmaceutical manufacturers. This year’s review includes the following 10 […]
2 min read
0
  1. Media & Marketing

How Payers Are Reacting to Insulin Price Changes

Today’s guest post comes from Nicole Mayer, Senior Analyst at MMIT. Nicole summarizes MMIT’s research on payers’ views of two crucial market changes: (1) the Inflation Reduction Act of 2022’s requirement to cap insulin prices at $35 for Medicare beneficiaries, and (2) manufacturers’ reduction in list prices for certain insulin products. She also discusses MMIT’s […]
2 min read
0
  1. Media & Marketing

Drug Channels News Roundup, November 2023: My $0.02 on Express Scripts’ Cost-Based Pricing, Mark Cuban vs. PBMs, Dual-WAC Strategies, Pharmacy Shakeout, and Adam vs. Rocky

I hope everyone enjoyed the Thanksgiving holiday. Now that you’ve stretched your stomach, it’s time to stretch your mind with some food for thought. In this issue: A reality check on Express Scripts’ purported “cost-based” pharmacy network Mark Cuban explains how and why the PBM market will change Why two drug prices are better than […]
2 min read
0
  1. Trends & External Forces

Why 340B Reform Could Happen in 2025 (video)

During my recent Drug Channels Outlook 2025 video webinar, I tackled a wide range of crucial topics—including the controversial 340B Drug Pricing Program. As I explain in this video excerpt, we may finally see reform of this rapidly expanding program. What’s more, implementing the Inflation Reduction Act will disrupt the current operations of the 340B […]
2 min read
0
  1. Trends & External Forces

At the Breaking Point: The Unsustainable Future of Government Drug Discount Programs

Today’s guest post comes from Gavin Magaha, Senior Director of External Affairs and Policy at Kalderos. Gavin discusses the three key reasons for duplicate discounts between the 340B Drug Pricing Program and the Medicaid Drug Rebate Program. He then explains Oregon’s novel approach to fixing the problem. To learn more, register for Kalderos’ August 21, […]
2 min read
0
  1. Trends & External Forces

Available for Preorder: The 2023-24 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors

On October 10, 2023, Drug Channels Institute will release 2023-24 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors. This report—our fourteenth edition—remains the most comprehensive, fact-based tool for understanding and analyzing the large and growing U.S. pharmaceutical distribution industry. 9 chapters, 300+ pages, 163 exhibits, 600+ endnotes: There is nothing else available that comes close […]
3 min read
0
  1. Media & Marketing

Mark Cuban: Five Ways that Big PBMs Hurt U.S. Healthcare–And How We Can Fix It (rerun)

This week, I’m rerunning some popular posts while I prepare for today’s live video webinar: The 340B Drug Pricing Program: Trends, Controversies, and Outlook. The webinar begins at 12:00 PM ET. Click here to see the original post from March 2024. Today’s guest post comes from Mark Cuban, co-founder of the Mark Cuban Cost Plus […]
2 min read
0
  1. Data & Insights

From Data Gaps to Revenue Gains: Harnessing the Power of Comprehensive Data to Drive GTN

Today’s guest post comes from Thomas Luby, Sr. Vice President, Business Development at PHIL. Thomas discusses the challenges brands face as they manage gross-to-net (GTN) performance while simultaneously enhancing patient access and adherence. He lists the key performance indicators that can help brands improve GTN. To learn more, watch PHIL’s free on-demand webinar: Four Patient Access […]
2 min read
0
  1. Sponsored

Repairing the Patient Journey: How Pharma Can Fix the Obvious–and Not So Obvious–Breaking Points of Nonadherence

Today’s guest post comes from Maria Kirsch, President, Patient Services, Krista Pinto, President, Deployment Solutions, and Mike Scott, Senior Vice President, Specialty Consulting at EVERSANA. Maria, Krista, and Mike discuss the key reasons why patients abandon drug therapy. They then describe EVERSANA’s approach for helping manufacturers and healthcare providers improve adherence and health outcomes. Learn […]
2 min read
0
  1. Media & Marketing

Four Crucial Questions about the Humira Biosimilar Price War (rerun)

This week, I’m rerunning some popular posts while I put the finishing touches on our new 2023-24 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors. Since I published the article below in July 2023, there have been three notable market develpoments: IQVIA has reported that as as of mid-2023, there was almost no adoption of […]
3 min read
0
  1. Data & Insights

Vanishing Act: Why Small Pharmacies Exited Medicare Part D Networks for 2025

Abracadabra! Small pharmacies have ghosted Medicare Part D’s preferred networks—no farewell party, no breakup text, just a quiet exit. A few months ago , DCI highlighted how the largest pharmacy chains are participating as preferred cost sharing pharmacies in the 2025 stand-alone prescription drug plan (PDP) networks. Today, we update our exclusive analysis of how […]
2 min read
0
Next